NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $15.67.

Several research firms have recently weighed in on NPCE. Cantor Fitzgerald raised their price objective on shares of NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. SVB Leerink assumed coverage on NeuroPace in a report on Tuesday, January 30th. They set an “outperform” rating and a $22.00 target price on the stock. Lake Street Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of NeuroPace in a report on Wednesday, December 27th. Morgan Stanley increased their price objective on shares of NeuroPace from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 6th. Finally, Leerink Partnrs restated an “outperform” rating on shares of NeuroPace in a research report on Tuesday, January 30th.

Insider Activity

In related news, insider Martha Morrell sold 1,923 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.08, for a total transaction of $28,998.84. Following the completion of the sale, the insider now directly owns 96,014 shares of the company’s stock, valued at $1,447,891.12. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 27.50% of the company’s stock.

Hedge Funds Weigh In On NeuroPace

Hedge funds have recently added to or reduced their stakes in the stock. Citigroup Inc. bought a new stake in NeuroPace in the third quarter valued at approximately $29,000. Virtu Financial LLC acquired a new position in shares of NeuroPace during the 4th quarter worth about $111,000. Barclays PLC grew its holdings in shares of NeuroPace by 9,085.6% in the 3rd quarter. Barclays PLC now owns 10,839 shares of the company’s stock valued at $105,000 after acquiring an additional 10,721 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of NeuroPace in the second quarter valued at about $63,000. Finally, Susquehanna International Group LLP bought a new stake in NeuroPace during the first quarter worth about $65,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Price Performance

Shares of NPCE stock opened at $13.50 on Friday. The stock’s fifty day simple moving average is $14.72 and its 200 day simple moving average is $11.24. NeuroPace has a one year low of $3.80 and a one year high of $18.15. The firm has a market cap of $354.83 million, a price-to-earnings ratio of -10.55 and a beta of 2.08. The company has a debt-to-equity ratio of 2.76, a current ratio of 5.71 and a quick ratio of 5.02.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, March 5th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.10. The company had revenue of $18.01 million for the quarter, compared to the consensus estimate of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative return on equity of 153.76%. On average, analysts expect that NeuroPace will post -1.14 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.